iBio Makes NYSE MKT Section 610(b) Public Announcement
September 19 2017 - 5:55PM
iBio, Inc. (NYSE AMERICAN:IBIO) – iBio, a leader in developing
plant-based biopharmaceuticals, today announced that, as previously
disclosed in its Annual Report on Form 10-K for the year ended June
30, 2017 filed on September 15, 2017 with the Securities and
Exchange Commission, the audited financial statements for the year
ended June 30, 2017 included in the 10-K contained an audit opinion
from its independent registered public accounting firm, which
included a going concern emphasis of matter paragraph.
This announcement is made pursuant to NYSE MKT
Company Guide Section 610(b), which requires separate public
announcement of the receipt of an audit opinion containing a going
concern paragraph. This announcement does not represent any
change or amendement to the Company’s consolidated financial
statements or to its Annual Report on Form 10-K for the year ended
June 30, 2017.
About iBio, Inc.
iBio, a leader in developing plant-based
biopharmaceuticals, provides a range of product and process
development, analytical, and manufacturing services at the
large-scale development and manufacturing facility of its
subsidiary iBio CDMO LLC in Bryan, Texas. The facility houses
laboratory and pilot-scale operations, as well as large-scale
automated hydroponic systems capable of growing over four million
plants as "in process inventory" and delivering over 300 kilograms
of therapeutic protein pharmaceutical active ingredient per year.
iBio applies its technology for the benefit of its clients and the
advancement of its own product interests. The Company’s pipeline is
comprised of proprietary candidates for the treatment of a range of
fibrotic diseases including idiopathic pulmonary fibrosis, systemic
sclerosis, and scleroderma. IBIO-CFB03, based on the Company's
proprietary gene expression technology, is the Company’s lead
therapeutic candidate being advanced for IND development.
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED
TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS
COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND
THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY
ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND
DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS
THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN
THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
Source: iBio, Inc.
CONTACT:Stephanie CarringtonICR, Inc.
stephanie.carrington@icrinc.com 646-277-1282
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024